<DOC>
	<DOC>NCT02403323</DOC>
	<brief_summary>This two-part, open-label extension and safety monitoring study will examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144.</brief_summary>
	<brief_title>Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Part 1 Openlabel Extension: Patients previously enrolled in etrolizumab Phase III study GA29144 who meet the eligibility criteria for openlabel etrolizumab as described in the protocol Part 2 Safety Monitoring: Patients who participated in etrolizumab Phase III study GA29144 and are not eligible or choose not to enter Part 1 Patients who transfer from Part 1 Completion of the 12week safety followup period prior to entering Part 1 Openlabel Extension: Any new, significant, uncontrolled condition Part 2 Safety Monitoring: No exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>